These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1642 related articles for article (PubMed ID: 18083107)

  • 1. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
    Rikova K; Guo A; Zeng Q; Possemato A; Yu J; Haack H; Nardone J; Lee K; Reeves C; Li Y; Hu Y; Tan Z; Stokes M; Sullivan L; Mitchell J; Wetzel R; Macneill J; Ren JM; Yuan J; Bakalarski CE; Villen J; Kornhauser JM; Smith B; Li D; Zhou X; Gygi SP; Gu TL; Polakiewicz RD; Rush J; Comb MJ
    Cell; 2007 Dec; 131(6):1190-203. PubMed ID: 18083107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.
    Haake SM; Li J; Bai Y; Kinose F; Fang B; Welsh EA; Zent R; Dhillon J; Pow-Sang JM; Chen YA; Koomen JM; Rathmell WK; Fishman M; Haura EB
    Clin Cancer Res; 2016 Nov; 22(22):5605-5616. PubMed ID: 27220961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.
    Jun HJ; Johnson H; Bronson RT; de Feraudy S; White F; Charest A
    Cancer Res; 2012 Aug; 72(15):3764-74. PubMed ID: 22659450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
    Cheng M; Ott GR
    Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
    Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
    Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
    Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical screening for oncogenic tyrosine kinase activation.
    Pulford K; Delsol G; Roncador G; Biddolph S; Jones M; Mason DY
    J Pathol; 1999 Apr; 187(5):588-93. PubMed ID: 10398126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
    Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
    J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling networks assembled by oncogenic EGFR and c-Met.
    Guo A; Villén J; Kornhauser J; Lee KA; Stokes MP; Rikova K; Possemato A; Nardone J; Innocenti G; Wetzel R; Wang Y; MacNeill J; Mitchell J; Gygi SP; Rush J; Polakiewicz RD; Comb MJ
    Proc Natl Acad Sci U S A; 2008 Jan; 105(2):692-7. PubMed ID: 18180459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.
    Schweppe DK; Rigas JR; Gerber SA
    J Proteomics; 2013 Oct; 91():286-96. PubMed ID: 23911959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
    Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
    Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.
    Amin AD; Rajan SS; Liang WS; Pongtornpipat P; Groysman MJ; Tapia EO; Peters TL; Cuyugan L; Adkins J; Rimsza LM; Lussier YA; Puvvada SD; Schatz JH
    Cancer Res; 2015 Jul; 75(14):2916-27. PubMed ID: 26018086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
    Lin J; Sun T; Ji L; Deng W; Roth J; Minna J; Arlinghaus R
    Oncogene; 2007 Oct; 26(49):6989-96. PubMed ID: 17486070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.